Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor. Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for the treatment of several malignancies.This phase II trial studies the efficacy and safety of penpulimab in the treatment of MPP patients who fail to other systemic therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The objective response rate (ORR)
Timeframe: At the end of Cycle 3(each cycle is 21 days)
The disease control rate (DCR)
Timeframe: At the end of Cycle 3(each cycle is 21 days)